Learn About Myxoid Liposarcoma

What is the definition of Myxoid Liposarcoma?
Myxoid liposarcoma is a subtype of liposarcoma, tumors that arise in the body's fat tissue. Other categories of liposarcoma include well-differentiated; dedifferentiated; round cell; and pleomorphic. Round cell and Myxoid liposarcomas are sometimes grouped together into one category known as myxoid/round cell liposarcoma (MRCLS). In adults, liposarcomas are the most common type of soft tissue sarcoma. The cause of liposarcomas is not well-established but trauma has been implicated in some cases. Myxoid liposarcomas generally arise in the lower extremities. Symptoms may vary depending on the location of the tumor but may include swelling; decreased range of motion; numbness; fatigue; abdominal pain; weight loss; nausea; and vomiting. Many patients with liposarcoma have no symptoms until the tumor is large and interferes with neighboring structures.
Save information for later
Sign Up
What are the alternative names for Myxoid Liposarcoma?
  • Myxoid liposarcoma
  • Myxoid/round cell liposarcoma
  • Myxoliposarcoma
Who are the top Myxoid Liposarcoma Local Doctors?
Learn about our expert tiers
Learn more
What are the latest Myxoid Liposarcoma Clinical Trials?
A Phase II Study, With a Safety lead-in, to Evaluate ATX-101, a Peptide Drug Targeting PCNA, in Advanced Dedifferentiated Liposarcoma and Leiomyosarcoma

Summary: The purpose of this study is to evaluate the effectiveness of a new investigational drug, ATX-101, for the treatment of dedifferentiated liposarcoma (LPS) and leiomyosarcoma (LMS). ATX-101 is an intravenous (IV) drug which blocks the interaction of a protein called PCNA with a number of stress response proteins. These interactions are thought to be important for cancer cell survival and growth. AT...

Match to trials
Find the right clinical trials for you in under a minute
Get started
A European, Multicenter, Randomized, Open-label, Phase II Trial Aiming to Assess the Clinical and Biological Activity of an Anti-PD-L1 (Atezolizumab) in Operable Localised Soft Tissue Sarcomas Patients to be Treated With Radiotherapy

Summary: This multicentric, randomised, Phase II trial will use a pick-the-winner design in order to evaluate the clinical and biological activity of atezolizumab when combined with pre-operative or post-operative radiotherapy in STS patients. Following Inform Consent Form (ICF) signature, eligible patients will be randomised (1:1:1) to receive: Arm A: Radiotherapy followed by atezolizumab then surgery. Ar...

Who are the sources who wrote this article ?

Published Date: May 02, 2022
Published By: Genetic and Rare Diseases Informnation Center

What are the Latest Advances for Myxoid Liposarcoma?
Evaluation of prognostic factors and oncological outcomes in patients with limb-localized myxoid liposarcoma.
A Phase 1/2 Trial Combining Avelumab and Trabectedin for Advanced Liposarcoma and Leiomyosarcoma.
Tired of the same old research?
Check Latest Advances
Myxoid liposarcoma originating in the retroperitoneum with metastasis to the calcaneus: a rare case report and review of literature.